samedan logo

home > ict > summer 2021 > how contingency plans became the new normal
International Clinical Trials

How Contingency Plans Became the New Normal

Over the last decade, there has been increasing interest in mobile health (mHealth) and wearables. The general population has been tracking their steps, checking their heart rates, and monitoring their sleep patterns. Meanwhile, the clinical trial industry has been exploring decentralised trials and remote monitoring options as a way of alleviating the travel burden that patients and CRAs often endure in the course of a trial, especially in rare disease studies where hard-tofind patient populations, as well as the diseases themselves, make trials especially complex. Then the pandemic arrived, and with both patients and clinical trial personnel needing to stay away from sites, the tools and techniques that had been a ‘nice-to-have’ option became a necessity. A year later, the industry has proof that mHealth and remote monitoring deliver clean, concise data far more conveniently than the traditional methods. Now, these new strategies are no longer contingency plans; bringing the clinical trial to the patient is the new normal.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

About the Author

Anthony Poynton, Senior Director, Program Delivery, Rare Disease and Pediatrics, is Premier Research's senior liaison for clinical research in rare diseases and paediatrics, serving as sponsors’ primary point of contact for these clinical programmes and leading teams assigned to these studies. He oversees project scope, schedule, costs, and quality performance to ensure timely project execution and customer satisfaction. Anthony has 17 years of experience in the contract research, pharma, and biotech fields. He joined Premier Research in 2016 as Director of Project Management, overseeing efforts to improve customer satisfaction and drive best practices in innovation and continuous improvement. Prior to joining the company, he held similar positions in the areas of rare and orphan diseases, paediatrics, oncology, gastroenterology, nephrology, and dermatology.
Print this page
Send to a friend
Privacy statement
News and Press Releases

ACG Films & Foils and Danapak Flexibles A/S enters Strategic Partnership for India

Today, ACG, one of the world's most integrated pharmaceutical suppliers, announced its strategic partnership with Danapak Flexibles A/S, the global market leader in packaging for high barrier Transdermal Drug Delivery systems. The partnership will translate into better services to existing and new customers of Danapak Flexibles in India.
More info >>

White Papers



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement